Menu Search
Equities

Shanghai Yizhong Pharmaceutical Co Ltd

688091:SHH

Shanghai Yizhong Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)26.63
  • Today's Change0.37 / 1.41%
  • Shares traded993.51k
  • 1 Year change-36.96%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in CNYView more

In 2023, Shanghai Yizhong Pharmaceutical Co Ltd increased its cash reserves by 28.83%, or 203.64m. Cash Flow from Investing totalled 116.49m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 86.55m in cash from operations while cash generated from financing totalled 591.70k.
Cash flow per share--
Price/Cash flow per share--
Book value per share7.10
Tangible book value per share7.05
More ▼

Balance sheet in CNYView more

Shanghai Yizhong Pharmaceutical Co Ltd has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 914.76m.
Current ratio12.80
Quick ratio12.37
Total debt/total equity0.0219
Total debt/total capital0.0214
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.